Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 11Completed 6Not yet recruiting 4Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 390Neoplasms 382Lung Neoplasms 266Multiple Myeloma 246Colorectal Neoplasms 235Neoplasm Metastasis 217Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 166Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 141Carcinoma, Renal Cell 141Lymphoma 137Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 124Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 119Head and Neck Neoplasms 115Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 100Lymphoma, Follicular 96Sarcoma 95

Interventions

Social Determinants of Health 2Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Drug-Related Side Effects and Adverse Reactions × 1 year × Clear all
NCT05096338 2026-03-23

PCT

Abramson Cancer Center at Penn Medicine

Active not recruiting
200 enrolled
Genitourinary

Cardiovascular Diseases, Prostatic Neoplasms, Drug-Related Side Effects and Adverse Reactions, Cardiotoxicity

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT05078190 2025-11-06

CCT2

Abramson Cancer Center at Penn Medicine

Active not recruiting
200 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases, Drug-Related Side Effects and Adverse Reactions, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡